Core Viewpoint - NEXGEL, Inc. has rescheduled its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026, to provide shareholders with more details regarding a proposed transaction with Celularity Inc. [1] Company Overview - NEXGEL, Inc. is a leading provider of healthcare, beauty, and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogel products for various applications [3] - The company has been developing and manufacturing electron-beam, cross-linked hydrogels for over two decades and has established brands such as SilverSeal®, Hexagels®, Turfguard®, Kenkoderm®, and Silly George® [3] - NEXGEL maintains strategic contract manufacturing relationships with prominent consumer healthcare companies [3] Financial Reporting - The company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission on March 31, 2026 [2] - The details for the fourth quarter and full year 2025 financial results conference call are as follows: Date: April 8, 2026, Time: 4:30 P.M. ET, Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International) [3]

Core Viewpoint - NEXGEL, Inc. reported flat revenue year-over-year for Q3 2025, but showed improvement in Adjusted EBITDA loss, indicating operational efficiencies and growth in contract manufacturing and consumer branded products [3][4][8]. Financial Performance - Revenue for Q3 2025 was $2.93 million, a slight decrease of 0.20% from $2.94 million in Q3 2024 [4][10]. - Cost of revenues decreased to $1.69 million from $1.79 million in Q3 2024, attributed to lower material costs and reduced amortization and depreciation [5][10]. - Gross profit increased to $1.24 million, with a gross profit margin of 42.4%, up from 39.3% in Q3 2024 [6][10]. - Selling, general and administrative expenses rose slightly to $1.96 million from $1.94 million in Q3 2024, mainly due to increased compensation and consulting fees [7][10]. - Net loss attributable to NEXGEL stockholders was $0.65 million, an improvement from a net loss of $0.69 million in Q3 2024 [8][10]. Operational Highlights - The company experienced stable performance in contract manufacturing and branded products, with growth driven by partnerships and new customer onboarding [3][4]. - NEXGEL's consumer brands are gaining traction through new product launches in beauty and skincare [3]. Cash Position - As of September 30, 2025, NEXGEL had a cash balance of approximately $938 thousand and a restricted cash balance of $920 thousand, supported by $1 million in non-dilutive capital from STADA [9][10]. Shareholder Information - As of November 11, 2025, NEXGEL had 8,143,133 shares of common stock outstanding [9].

Core Insights - NEXGEL, Inc. has appointed Steve Ciardiello, CPA, to its Board of Directors, bringing over 25 years of experience in financial leadership and corporate governance [1][2] - The CEO of NEXGEL, Adam Levy, expressed confidence that Ciardiello's financial acumen will be valuable as the company enters a new growth phase [2] - Ciardiello, currently the Chief Accounting Officer at Shutterstock, has a strong background in financial transformation and operational efficiency [2] Company Overview - NEXGEL is a provider of healthcare, beauty, and over-the-counter products, specializing in ultra-gentle, high-water-content hydrogels [3] - The company has been developing and manufacturing electron-beam, cross-linked hydrogels for over two decades [3] - NEXGEL's product brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm®, and Silly George®, and it has strategic manufacturing relationships with leading consumer healthcare companies [3]